Trial Profile

Feasibility and Efficacy of Perioperative Nivolumab With or Without Relatlimab for Patients With Potentially Resectable Hepatocellular Carcinoma (HCC)

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 16 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Nivolumab (Primary) ; Relatlimab (Primary)
Indications Carcinoma; Liver cancer
Focus Adverse reactions

Most Recent Events

10 Jun 2025 Planned End Date changed from 1 Jun 2026 to 1 Dec 2026.
10 Jun 2025 Planned primary completion date changed from 1 Jun 2025 to 1 Dec 2025.
29 Apr 2021 Planned End Date changed from 1 Jun 2025 to 1 Jun 2026.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com